(Q38555723)

4 September 2017

1 reference

title

New pharmacotherapy for Parkinson's disease (English)

1 reference

4 September 2017

0 references

1 reference

M D Gottwald

1

1 reference

4 September 2017

J L Bainbridge

2

1 reference

4 September 2017

G A Dowling

3

1 reference

4 September 2017

M J Aminoff

4

1 reference

4 September 2017

B K Alldredge

5

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 October 1997

1 reference

Annals of Pharmacotherapy

4 September 2017

published in

1 reference

4 September 2017

volume

31

1 reference

4 September 2017

issue

10

1 reference

4 September 2017

page(s)

1205-1217

1 reference

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Methods of managing levodopa-induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Dopamine receptor interactions: some implications for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

The neostriatal mosaic: multiple levels of compartmental organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Concentration-effect relationship of levodopa in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Pergolide in the treatment of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Assessment of extrapyramidal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Neuropsychological changes in a prospectively followed cohort of homosexual and bisexual men with and without HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809703101014

10.1177/106002809703101014

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference